Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 15 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
- In combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Summary
- Binimetinib (Mektovi) is used in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma and non-small cell lung cancer, specifically those carrying a BRAF V600E or V600K mutation.
- The drug has shown superior efficacy to other double combination therapies such as dabrafenib + trametinib and vemurafenib + cobimetinib, particularly in terms of overall response rate and fewer serious adverse events.
- In comparison to monotherapies, binimetinb (Mektovi) combined with encorafenib demonstrated more favorable outcomes including better progression-free survival rates, overall survival rates, objective response rates along with similar constitutional and cardiac profiles but slightly worse gastrointestinal profiles.
- However when compared to BRAF inhibitor monotherapy it was associated with an increased risk of cardiovascular adverse events including pulmonary embolism, decrease in left ventricular ejection fraction and arterial hypertension.
- A total of 5 systematic reviews/meta-analyses were reviewed which provided evidence on the effectiveness and safety profile of binimetnimb (Mektovi).
- Despite its benefits for cutaneous melanoma patients carrying specific mutations; uveal melanoma showed little responsiveness towards MEK inhibitors like binimtenimb (Mektovi), suggesting that novel treatments are needed for this patient population.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Mektovi (binimetinib) Prescribing Information. | 2023 | Array BioPharma Inc., Boulder, CO |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). | 2021 | ACTAS Dermo-Sifiliográficas |
| Systemic therapy for melanoma: ASCO guideline. | 2020 | American Society of Clinical Oncology |